Protein Biomarker Identified for MS May Predict Disease Severity, Treatment Response

October 16th, 2016

A newly discovered potential biomarker of multiple sclerosis (MS) may help to distinguish between people who will go on to have less severe disease and those in whom the disease will progress, researchers at Linköping University in Sweden report. The biomarker’s discovery came through an investigation into the immune system of MS patients, which behaves differently in these people than it does in those without the disease.

Living Well With MS: Exercise

March 19th, 2016

An exercise program needs to fit the capabilities and limitations of the individual. It may need to be adjusted as changes occur in MS symptoms. A physical therapist experienced with MS can be helpful in designing, supervising and revising an exercise program. Any person with MS who is initiating a new exercise program should also consult with a physician before starting. Periods of exercise should be carefully timed to avoid the hotter periods of the day and prevent excessive fatigue. With some guidelines, an exercise program can help maintain good health.

Outcomes of Cognitive-Behavioral Treatment for Insomnia on Insomnia, Depression, and Fatigue for Individuals with Multiple Sclerosis

March 4th, 2016

These results strongly suggest that CBT-I may serve as an effective clinical intervention for individuals with MS who report symptoms of insomnia. Given the considerable overlap of experiences of insomnia, depression, and fatigue in people with MS, CBT-I may also be helpful in identifying areas that may require additional clinical intervention for persistent symptoms of depression and fatigue.

Stem Cell Treatment In the News

February 22nd, 2016

In November 2015, the International Conference on Cell-Based Therapy for Multiple Sclerosis was convened by the National MS Society and the European Committee for Treatment and Research in Multiple Sclerosis, bringing leading researchers and clinicians together to confer on clinical trials needed to provide answers about which types of cells, which route of delivery, and which types and stages of disease, would be the most promising approach for treating MS. A summary and consensus on next steps will be published by the conference organizers, with recommendations to help speed the development of new cell-based treatment solutions.

Your Patients with Multiple Sclerosis have Set Wellness as a High Priority— And the National Multiple Sclerosis Society is Responding

November 14th, 2015

Achieving wellness is a high priority for people living with multiple sclerosis (MS). They want to know what they can do today to feel their best, and whether lifestyle interventions can impact the course of the disease. People with MS are also among the most informed, engaged, and self-advocating patients with chronic illness—proactively seeking information through a variety of channels.

John Marmarou, DPT, MSCS Speaks at the 2015 National Multiple Sclerosis Society Annual Meeting

November 9th, 2015

Thank you to the National Multiple Sclerosis Society for having John Marmarou, DPT, MSCS speak at this year’s annual meeting.

John is pictured with Piper McNealy, Chairman Of The Board of Trustees of the Greater New England Chapter and Linda Guiod, Executive Vice President of Programs, Services, and Advocacy. The talk focused on the outcome data of work accomplished by Total Rehab & Fitness MS patients, which is starting to catch national attention.

Thank you to everyone who attended the event and for all of your support!

With Piper and Linda  2015 annual talk

Cognitive rehabilitation improves brain performance in patients with MS

September 23rd, 2015

In a new study published in the March issue of Radiology, functional magnetic resonance imaging (fMRI) shows that cognitive rehabilitation changes brain function and improves cognitive performance in patients with relapsing-remitting multiple sclerosis (MS).

“These results prompt the use of specific computer-based rehabilitation programs to treat deficits in selected neuropsychological domains in patients with relapsing-remitting MS,” said the study’s lead author, Massimo Filippi, M.D., professor of neurology at the San Raffaele Vita-Salute University and director of the “BrainMap” interdepartmental research program and the Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute San Raffaele, Milan, Italy. “They also suggest that fMRI might provide useful metrics to monitor the effects of rehab in MS.”…

Mental visual imaging training improves multiple sclerosis patients’ well-being

September 6th, 2015

The MVI program to improve patients’ AM/EFT is based on the ability to mentally construct scenes and pay close attention to details in the mind’s eye. The program comprised four steps, with mental visualisation exercises of increasing difficulty, during which the attending neuropsychologist provided continuous guidance (as much as necessary) to the patient, probing to recall general aspects to more detailed ones, adopting a “funnel-approach,” and learning to work in a sequential manner…

High salt intake may increase MS risk for people with genetic susceptibility

August 16th, 2015

By offering an explanation as to how eating too much salt may contribute to the disease, a new study improves our understanding of what can trigger multiple sclerosis in some people…

Depression in Multiple Sclerosis

July 25th, 2015

Depression, which is one of the most common symptoms of MS, is associated with considerable morbidity and mortality. Depression reduces quality of life, has a negative impact on adherence, and is known to worsen cognitive function and other MS symptoms such as fatigue and pain…

CMSC INforMS: Genentech’s ocrelizumab Reduced Both Relapses and Disability Progression versus Rebif

July 18th, 2015

Treatment with ocrelizumab significantly reduced the annualized relapse rate (ARR) over a two-year period compared with interferon beta-1a, the primary endpoint in both studies. Ocrelizumab also significantly reduced the progression of clinical disability compared with interferon beta-1a, as measured by the Expanded Disability Status Scale (EDSS). Additionally, treatment with ocrelizumab led to a significant reduction in the number of lesions in the brain (areas of disease activity) compared with interferon beta-1a, as measured by MRI…

Jimmo v. Sebelius: Federal Settlement Invalidated Medicare Improvement Requirement

July 3rd, 2015

Medicare coverage does not depend on the potential for improvement, but rather on the need for skilled care (and other criteria particular to the care-setting). The Jimmo settlement offers hope that Medicare beneficiaries like Mrs. P will not have to forgo necessary care or deal with the stress of coverage denials based on an Improvement Standard…

The Inspiring Success Story of Christina Aivazoglou

June 28th, 2015

Even the most dire of situations have light at the end of the tunnel with treatment, determination, and hope.


Finding The Right Balance

June 20th, 2015

We all fall down. But while a tumble for a toddler is a learning experience, and a stumble for an adult is usually just embarrassing, for older people it can be a serious, even fatal, incident.

While aerobic exercise and strength training trigger brain chemicals that enhance neuron growth and survival, balance and coordination call on higher-level cognitive processes that seem to increase the number of synapses connecting the neurons…


Total Rehab and Fitness makes a major (muddy) splash at Muckfest MS in Philadelphia!

June 16th, 2015

The staff, along with some friends, of Total Rehab and Fitness participated in this year’s Muckfest MS, raising $3,732 for the cause! Thank you to all those who contributed and we hope you enjoy these pictures of the event, we had a blast!

Total Rehab and Fitness Muckfest MS 2015

To see all of the photos visit our Facebook page –



Exercise, Behavioral Therapy Improves Outcomes in Multiple Sclerosis Patients

May 28th, 2015

A continuous disease management program of prescribed exercise for patients with multiple sclerosis (MS) successfully reversed disease-related decline in the majority of patients, according to data presented at the Consortium of Multiple Sclerosis Centers 2015 Annual Meeting…




MS Trial Alert: Researchers in California, Colorado, New Mexico and Pennsylvania Recruiting Women with Progressive or Relapsing MS for Study of Estriol to Improve Cognition

May 8th, 2014

Investigators in California, Colorado, New Mexico and Pennsylvania are recruiting 64 women with MS relapsing-remitting, secondary-progressive, or primary-progressive for a 12-month study in which the sex hormone estriol will be compared with inactive…,-Colorado



Research to Tackle MS Symptoms and Progression Among Reports from the American Academy of Neurology Meeting

May 2nd, 2014

Read blogs from members of the Society’s research team on topics including the latest research on tackling MS symptoms, progressive MS and new treatment approaches. reporting from the American Academy of Neurology’s Annual Meeting in Philadelphia…



TRF named Corporate Champion of the Year

The National MS Society helps each person affected by MS in our area address the challenges of living with MS. We do so by raising funds for cutting-edge research, driving change through advocacy, facilitating professional education and providing programs… 



Genzyme Announces it Will Resubmit Lemtrada Application to the FDA

April 7, 2014

Today (April 7) Genzyme, a Sanofi company, announced it will be resubmitting its application to the U.S. Food and Drug Administration for approval of Lemtrada™ (alemtuzumab) as a treatment for relapsing MS in the United States.  The company’s previous application was…



National MS Society Invests $29 Million in New Research to Stop Multiple Sclerosis, Restore Function and End MS Forever

March 27, 2014

The National MS Society has committed another $29 million to support an expected 83 new MS research projects and training awards. These are part of a comprehensive research strategy aimed at stopping MS and restoring function that has been lost…$29-Million-in-New-Res



CMSC INforMS: Slowing of Brain Atrophy Sustained at 3 Years in Patients Treated with Lemtrada

Wednesday, April 30, 2014

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today new magnetic resonance imaging (MRI) data from the Lemtrada (alemtuzumab) clinical development program…



New Guideline from the American Academy of Neurology Addresses Potential Benefits and Risks of Specific Complementary and Alternative Medical Approaches to Treating MS

March 24, 2014

The American Academy of Neurology, an association of neurologists and neuroscientists dedicated to promoting high-quality care for people with nervous system disorders, has released a  on the use of complementary and alternative medicine (CAM) in MS. The guideline…